Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp
The company states: 'Bicara Therapeutics (BCAX) announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line recurrent/metastatic head and neck squamous cell carcinoma on the 2025 American Society of Clinical Oncology Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset, including overall survival and duration of response data, following an oral presentation of the data at the ASCO Annual Meeting. Ficerafusp alfa is a first-in-class bifunctional antibody designed to enhance tumor penetration by breaking barriers within the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta.' 'We are pleased to present the fulsome dataset from our Phase 1/1b trial of ficerafusp alfa in patients with recurrent/metastatic head and neck squamous cell carcinoma during our upcoming oral presentation at ASCO,' said David Raben, MD, Chief Medical Officer of Bicara Therapeutics. 'The interim data featured in the ASCO abstract demonstrate encouraging signals that represent a meaningful improvement over historical benchmarks in patients with HPV-negative disease, a population with high unmet need and worse survival outcomes than those with HPV-positive disease. Notably, we're encouraged to see how ficerafusp alfa, specifically designed to drive tumor penetration within the tumor microenvironment, is leading to deep, and now, durable responses that appear to be translating to prolonged overall survival.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Engadget
an hour ago
- Engadget
Directive 8020's rewind feature makes play-your-own-survival-horror easier for completionists
Supermassive's well-regarded interactive survival horror series, the Dark Pictures Anthology, is ready for its second season. Directive 8020 will be its first entry and was available to play in demo form at SGF 2025, even if it was heavily weighted with cutscenes and context-setting preamble. The demo kicked off with a meeting between Young and Stafford, marking the anniversary of Young's father's death, who was also a long-time friend of Stafford's – the commander of the space mission that Young is also bound for. The plot then leaps four years forward, placing us aboard the spaceship Cassiopeia. Oh and it's somehow overrun by some fungal, sentient alien goop. Worse still, but also a horror staple, the goop is coalescing into almost-perfect copies of the human crew. Trust no-one! To view this content, you'll need to update your privacy settings. Please click here and view the "Content and social-media partners" setting to do so. When the hydroponics bay is overrun by an alien substance, two crewmates Cernan and Stafford, have to fight their ET doppelgangers. Finally, I got to play (but only for a few minutes), moving stealthily around the lower deck of the hydroponics bay while my alien copy (now fungal and angry) tried to hunt me down. Fortunately, you're equipped with a scanner to mark where the aliens were last seen, and after triggering a nearby hydroponic pod to distract, I made my way up the ladder. This was one of three ways to play this section, handily introducing a new mechanic for The Dark Pictures' second run: Turning Points. Using this feature, you can rewind to these decision trees, allowing you to replay sections and explore different options or alter the outcome. This is an interesting change for the series. In previous games, while you could rewind to replay entire sections in macro, there was no way to change a single micro decision. I discussed this with my colleague Jessica Conditt, and we're both the kind of players to continue with our terrible decisions in games like Directive 8020 , the Dark Pictures Anthology, Until Dawn and the rest. Fortunately, then, Directive 8020 will include a hard-boiled Survivor Mode – with no rewinds. The demo shifted back to a more narrative focus and cutscenes, briefly interrupted by the possibility that one crew member (specifically, the CEO funding the whole operation) might be an alien. Did I pull the trigger? Nope. I'll have to wait til the October launch to know if that was the right decision to make. Directive 8020 launches on 2nd October, 2025 on PlayStation 5, Xbox Series X|S, and Steam.
Yahoo
an hour ago
- Yahoo
NVIDIA stock gains as Huang kicks off European tour with UK his first stop
NVIDIA shares added to recent gains Monday as CEO Jensen Huang set his sights on Europe. Huang, alongside U.K. Prime Minister Sir Keir Starmer, kicked off London Tech Week on Monday. The event underscored a pivotal change in the U.K.'s approach to technology, transforming it from a startup-centric domain to a matter of national policy. This strategic shift is supported by substantial investments in human capital, technological platforms, and strategic partnerships. By 11:40AM ET, NVIDIA's (NASDAQ:NVDA) stock was up 0.94% to $143.03. Huang emphasized AI's transformative potential across various sectors, predicting that "every industry in the U.K. will be a tech industry" due to AI. Starmer shared his administration's focus on integrating AI across all government departments to enhance the lives of U.K. citizens. He highlighted the U.K.'s robust AI community, significant capital investments in AI, and the nation's commitment to becoming a hub for AI research and development. NVIDIA is set to further its investment in the U.K. by establishing an AI lab and collaborating with the government to advance the AI skills of local developers. These initiatives aim to create a self-reinforcing cycle where infrastructure investments spur more research, leading to breakthroughs and the growth of new companies. The collaboration between the U.K. government and NVIDIA extends to several key projects. The NVIDIA Deep Learning Institute will support a national AI skills initiative, training developers in advanced AI techniques. NVIDIA's new AI Technology Center in the U.K. will focus on research in embodied AI, material science, and earth system modeling. The U.K.'s Financial Conduct Authority is incorporating NVIDIA technology into its innovation sandbox, and a partnership has been announced to accelerate AI-native 6G research. Additionally, the Isambard AI supercomputer, powered by NVIDIA, is expected to become operational this summer. A significant commitment from the U.K. government involves an investment of approximately £1 billion in AI research compute by 2030, with funding beginning this year. This investment aligns with Prime Minister Starmer's vision of "sovereign AI ambitions," which encompasses more than technology—it's about encapsulating a nation's culture and heritage within AI development. NVIDIA's engagement in Europe is not limited to the U.K. In Sweden, Germany, and France, NVIDIA is collaborating with various partners to build national AI infrastructures and supercomputers, as well as establishing Europe's largest AI Campus in the Paris region. NVIDIA's dedication to the U.K. is evident, with a strong presence that includes over 1,700 Inception members and 500 employees. The company is partnering with leading U.K. enterprises to construct 'AI factories of the future' and is supporting a new wave of startups and scale-ups. The narrative will continue in Paris at NVIDIA GTC Paris, hosted live from VivaTech on June 11 at 11:00 a.m. CEST. Jensen Huang will deliver a keynote address, with a livestream available globally. The event is set to feature discussions on NVIDIA Blackwell, sovereign AI initiatives, and new regional partnerships, showcasing how European innovators are turning their AI ambitions into tangible infrastructure with NVIDIA's support. Related articles NVIDIA stock gains as Huang kicks off European tour with UK his first stop FTSE 100 today: Index edges lower, U.S.-China talks in focus; Alphawave soars Wolfe Research downgrades Equinix on valuation concerns after strong rally
